Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant et al.|Journal of Clinical Oncology|2012Cited by 4